Karyopharm's partner antengene receives approval in china for xpovio® (selinexor) for the treatment of patients with relapsed or refractory multiple myeloma

Newton, mass., dec. 17, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner, antengene corporation (antengene), has been granted conditional approval for marketing by the china national medical products administration (nmpa) for xpovio® (selinexor), a first-in-class, oral selective inhibitor of nuclear export (sine) compound, in combination with dexamethasone in patients with relapsed or refractory multiple myeloma who have received prior therapies and whose disease is refractory to at least a proteasome inhibitor, an immunomodulatory agent, and an anti-cd38 monoclonal antibody.
KPTI Ratings Summary
KPTI Quant Ranking